型肝炎直接作用剂的成本效益
Akshay Shetty1,2, Michelle Lee2, Julia Valenzuela2
1Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.
Expert review of pharmacoeconomics & outcomes research
|April 26, 2024
概括
直接作用抗病毒药物 (DAA) 为慢性肝炎C (HCV) 提供了有效的治疗方法. 本次审查评估了DAA的成本效益,这对于实现世卫组织的目标至关重要.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 公共卫生 公共卫生
- 卫生经济学 卫生经济学
背景情况:
- 直接作用抗病毒药物 (DAA) 已经彻底改变了慢性肝炎C (HCV) 治疗.
- 世界卫生组织的目标是到2030年消除HCV.
- 全基因型HCV疗法简化了治疗,并保持了高疗效.
研究的目的:
- 评估DAA治疗慢性HCV的成本效益.
- 在一般,肝硬化和脆弱患者群体中分析DAA的成本效益.
主要方法:
- 本研究是对现有文献进行评估的综述.
- 重点是对DAA治疗HCV的经济评估.
- 分析考虑了不同的患者人口统计和治疗场景.
主要成果:
- 对DAA的治疗显示出显著的临床疗效.
- 成本效益因人口和医疗保健系统而异.
- 成本和访问等障碍影响治疗的可扩展性.
结论:
- DAA治疗是HCV消除策略的基石.
- 有针对性的政策对于克服接入和成本障碍至关重要.
- 解决脆弱人群对于广泛的HCV根除至关重要.
相关概念视频
Retrovirus Life Cycles
45.9K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.9K
Dose-Response Relationship: Potency and Efficacy
4.4K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.4K


